Immunosuppressive therapy for cardiac transplantation
The immunosuppression of cardiac transplantation recipients is required indefinitely. Acute rejection episodes occur in most patients, and must be identified early and treated effectively. Acute rejection is seen most frequently during the first three postoperative months with both ‘conventional therapy’ and patients treated with cyclosporine. With standard immunosuppression, 90% of patients experience at least one rejection episode during this interval; with cyclosporine the incidence of this is somewhat less. The frequency of acute rejection declines substantially after 12 months (one episode per 748 patient days, compared to 1 per 35 patient days during the first three months) (1).
KeywordsAcute Rejection Cardiac Transplantation Antithymocyte Globulin Acute Rejection Episode Cyclosporine Therapy
Unable to display preview. Download preview PDF.
- 1.Jamieson SW, Bieber CP, Oyer PE: Immunosupression in Clinical Cardiac Transplantation. In: Immunosuppressive Therapy. (Salaman JR ed) MTP Press, pp 177-199, 1981.Google Scholar